Volpara Health, a global health technology software leader providing an integrated platform for the delivery of personalized breast and lung care, further expanded its footprint in the US lung screening market with a strategic relationship with Seattle-based lung AI company RevealDx.

Getty Images


September 27, 2021 — Volpara Health, a global health technology software leader providing an integrated platform for the delivery of personalized breast and lung care, further expanded its footprint in the US lung screening market with a strategic relationship with Seattle-based lung AI company RevealDx. This follows Volpara's recent collaboration agreement with leading US lung imaging company Riverain Technologies.

Approximately, 20–30% of lung computed tomography (CT) exams reveal lung nodules which need to be characterized as benign or malignant. The workup typically may include a follow-up lung CT exam in a few months or a surgical biopsy. In addition, many lung nodules are found incidentally when CT exams are performed for other reasons, such as shortness of breath, chest pain, or injury.

Volpara Lung software—an advanced, integrated, and adaptable reporting, tracking, and risk assessment solution for lung cancer screening—enables patient management from scheduling to diagnosis. The software offers structured reporting, customisable reminders, and more than 40 statistical reports to monitor and track patients—critical for outreach to patients overdue for their screening or follow-up exams. Volpara Lung automatically collects and validates all the required data elements for successful submission to the American College of Radiology Lung Cancer Screening Registry for reimbursement.

RevealDx, formerly known as Mindshare Medical, is focused on improving lung cancer outcomes by delivering the most advanced, radiomics and AI-enabled, lung cancer decision-support software to drive the optimal clinical pathway for each patient based on automated analytics of each lung nodule. Its patented, CE-marked software product integrates with picture archiving and communication systems (PACS) and scores nodules found in lung CT, informing better clinical decision making. Early clinical data for RevealAI-Lung suggests that many cancers can be detected earlier by using the AI nodule analysis rather than waiting for a scan in a few months' time, while simultaneously reducing false positives, with potentially significant cost savings.

"When we acquired MRS, we entered the lung cancer screening market with practice management software covering about 8% of the US lung cancer screening market. Since then, the benefits of lung cancer screening using low-dose CT have become more widely accepted globally, with the US doubling the number of people eligible, and countries like Australia starting the process of scoping out nationwide programs. Despite the clear benefits of screening in reducing mortality, a major issue those programs face is the number of false positive nodules found in routine screening as well as incidental findings. That differentiation of nodules is exactly what RevealDx has been focusing on. We look forward to working closely with them to bring that technology to market as part of an integrated lung cancer screening platform," said Ralph Highnam, Ph.D., Group CEO of Volpara.

"Volpara has a solid market share in lung, and we look forward to working closely with them to fully integrate RevealDx's AI capabilities into a wider lung offering both here in the United States and into Australia and New Zealand. By informing precision medicine, our products will improve follow-up for millions of patients. The ability to diagnose early, inform treatments, and optimise the total cost of care will be a game-changer," said Chris Wood, RevealDx CEO.

For more information: www.volparahealth.com


Related Content

News | Coronavirus (COVID-19)

December 7, 2022 — A research team at the Technical University of Munich (TUM) has, for the first time, produced dark ...

Time December 07, 2022
arrow
News | Coronavirus (COVID-19)

December 7, 2022 — Gross anatomy reveals three-dimensional shapes of pathology at a large scale. Histology, in contrast ...

Time December 07, 2022
arrow
News | Computed Tomography (CT)

December 2, 2022 — New CT technology outperforms conventional CT in detecting subtle damage in the lungs of patients ...

Time December 02, 2022
arrow
News | Computed Tomography (CT)

November 30, 2022 — Using a decade of weather and CT imaging data, researchers have identified specific weather ...

Time November 30, 2022
arrow
News | Ultrasound Imaging

November 29, 2022 — Samsung Electronics Co. Ltd. will be unveiling its latest artificial intelligence (AI) technologies ...

Time November 29, 2022
arrow
News | Mammography

November 29, 2022 — One in five women is likely to forgo additional testing after an abnormal finding on a screening ...

Time November 29, 2022
arrow
News | PACS

November 28, 2022 — At this week’s Radiological Society of North America (RSNA) annual meeting (November 27 – December 1 ...

Time November 28, 2022
arrow
News | Mammography

November 28, 2022 — The Radiological Society of North America (RSNA) has announced the launch of the RSNA Screening ...

Time November 28, 2022
arrow
News | Digital Radiography (DR)

November 28, 2022 — Konica Minolta Healthcare Americas, Inc., a leader in medical diagnostic imaging and healthcare ...

Time November 28, 2022
arrow
News | Artificial Intelligence

November 28, 2022 — Flywheel, a leading data management platform for biomedical research and collaboration, is creating ...

Time November 28, 2022
arrow
Subscribe Now